Exploring the Most Impactful Biopharma Mergers and Acquisitions in 2023: A Comprehensive List of the Top 10 Deals

In 2023, the biopharma industry witnessed a resurgence in mergers and acquisitions, with the top 10 deals totaling $115.8 billion, led by Pfizer's $43 billion merger with Seagen, indicating renewed confidence despite the absence of monumental transactions like Bristol Myers Squibb's acquisition of Celgene or AbbVie's takeover of Allergan, with notable focus on antibody-drug conjugates (ADCs) and neuroscience, including BMS' $14 billion bid for Karuna Therapeutics and AbbVie's $8.7 billion takeover of Cerevel Therapeutics.